Determination of Factor XIII Deficiency with Berichrom® F ... - Medcorp

FibrinstabilizationDetermination of Factor XIIIDeficiency with Berichrom® F XIIIFeatures●●●●●Fully automated assay on theBCS® and BCT® analyzersSTAT capabilityDetermination of acquiredFactor XIII deficienciesMonitoring of Factor XIIIsubstitution therapyPrecise results and controls:CPN Inter-assay CV < 5%CPP Inter-assay CV < 6%Essential knowledgeabout Factor XIIICongenital or acquired deficiency offibrin stabilizing Factor XIII impairscross-linking of fibrin, sometimesleading to severe bleeding. Lowlevels of Factor XIII (below 50%)result in insufficient cross-linkingof fibrin. Only at higher (normal)Factor XIII activity levels fibrin clotstability sufficient for normalhemostasis.Acquired Factor XIIIdeficiency 1 can beassociated with● Liver diseases 2● Inflammatory bowel diseases 3●●●●(Crohn’s disease, ulcerative colitis)Systemic hematologic diseasesDisseminated intra-vascularcoagulation (DIC)SepsisSurgery

We recommend monitoring F XIII in thefollowing situations:●●●●Patients with any form of liverdiseaseIntensive care patients withincreased risk of bleeding(twice per week)Unexplained bleedingImpaired wound healing●●●●Sepsis, (F XIII will decrease slowlyafter onset of sepsis)ThrombocytopeniaFactor XIII substitution therapy(daily monitoring)Inflammatory bowel disease(assessment of disease activity)The indication for F XIII substitutiontherapy is acute bleeding togetherwith measured F XIII deficiencybelow 50%. Controlled studies haveshown that prophylactic F XIIIsubstitution can reduce the numberof post-operative bleeding cases.Frequency of F XIII deficiency in hospitalized patients 4100%80%60%40%F Xlll 50%20%0%Chronic liver failureAcute liver failureSepsisAcute Myeloid Leukemia (AML)Chronic Myeloid Leukemia (CML)Malignant lymphomaPlasmacytomaInflammatory bowel diseasesCollagenic diseasesSchoenlein Hennoch purpuraVarious tumorsOrder information Berichrom® F XIIIProduct Code: Number of tests/kit on BCS® Number of tests/kit on BCT®OWSU 11 200 165References1.) Egbring, A. Kröniger, R. Seitz. Factor XIII Deficiency: Pathogenic Mechanisms and Clinical Significance. Seminars in Thrombosis and Hemostasis,Vol. 22 (5), 419 – 425 (1996).2.) G. Ballerini, D. Gemmati, S. Moratelli, P. Motelli, M.L. Serino. A Photometric Method For The Dosage of Factor XIII Applied to The Study of ChronicHepatopathies. Thrombosis Research (78),5, 451-456 (1995).3.) R. Lorenz, P. Olbert, P. Born. Factor XIII in chronic inflammatory bowel diseases. Seminars in Thrombosis and Hemostasis, Vol 22 (5), 451 -455 (1996).4.) R. Egbring, A. Kailing, H.G. Kehl, R. Seitz et.al. Disorders with severe acquired Factor XIII deficiency; lack of synthesis or increased consumption (DIC).J. McDonagh, R. Seitz, R. Egbring: F XIII second international conference, Marburg. Schattauer Verlag, Stuttgart-New York, 216-240, (1993).Berichrom, BCS and BCT are trademarks of Dade Behring MarburgGmbH and are registered in Germany and other countries. Informationgiven in this brochure is accurate at the time of going to press.Details in the package insert are binding in each individual case.This brochure is for use outside the USA. 131358 E 02/05DADE BEHRINGHoechster Strasse 7065835 Liederbach, Germanywww.dadebehring.com